- Home
- BACC vs AVIR Comparison
BACC vs AVIR Comparison
Compare BACC & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BACC
- AVIR
- Stock Information
- Founded
- BACC 2025
- AVIR 2012
- Country
- BACC United States
- AVIR United States
- Employees
- BACC N/A
- AVIR N/A
- Industry
- BACC
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- BACC
- AVIR Health Care
- Exchange
- BACC Nasdaq
- AVIR Nasdaq
- Market Cap
- BACC 279.6M
- AVIR 290.4M
- IPO Year
- BACC 2025
- AVIR 2020
- Fundamental
- Price
- BACC $10.01
- AVIR $3.19
- Analyst Decision
- BACC
- AVIR Hold
- Analyst Count
- BACC 0
- AVIR 1
- Target Price
- BACC N/A
- AVIR $6.00
- AVG Volume (30 Days)
- BACC 26.6K
- AVIR 452.2K
- Earning Date
- BACC 01-01-0001
- AVIR 11-07-2025
- Dividend Yield
- BACC N/A
- AVIR N/A
- EPS Growth
- BACC N/A
- AVIR N/A
- EPS
- BACC N/A
- AVIR N/A
- Revenue
- BACC N/A
- AVIR N/A
- Revenue This Year
- BACC N/A
- AVIR N/A
- Revenue Next Year
- BACC N/A
- AVIR N/A
- P/E Ratio
- BACC N/A
- AVIR N/A
- Revenue Growth
- BACC N/A
- AVIR N/A
- 52 Week Low
- BACC $9.95
- AVIR $2.46
- 52 Week High
- BACC $10.06
- AVIR $4.02
- Technical
- Relative Strength Index (RSI)
- BACC N/A
- AVIR 53.18
- Support Level
- BACC N/A
- AVIR $3.11
- Resistance Level
- BACC N/A
- AVIR $3.26
- Average True Range (ATR)
- BACC 0.00
- AVIR 0.11
- MACD
- BACC 0.00
- AVIR 0.02
- Stochastic Oscillator
- BACC 0.00
- AVIR 64.11
About BACC Blue Acquisition Corp. Class A Ordinary Shares
Blue Acquisition Corp is a blank check company.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).